

Biosimilar Studies Experience in Patients

	Lp.	Chemical substance	Indication
Biosimilar studies	1	Adalimumab	Plaque Psoriasis
	2	Adalimumab	Plaque Psoriasis
	3	Adalimumab	Plaque Psoriasis
	4	Adalimumab	Plaque Psoriasis
	5	Adalimumab	Rheumatoid arthritis
	6	Avelumab	Gastric cancer
	7	Bewacyzumab	Non-small-cell lung cancer
	8	Etanercept	Plaque Psoriasis
	9	Etanercept	Rheumatoid arthritis
	10	Pegfilgrastim	Neutropenia
	11	Pegfilgrastim	Neutropenia
	12	Rituximab	Rheumatoid arthritis
	13	Rituximab	Diffuse Large B-Cell Lymphoma (DLBCL)
	14	Rituximab	Rheumatoid arthritis
	15	Rituximab	Non-Hodgkin Lymphoma

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q